Introductory Comment Use of Terminology
Throughout this Accepted Address on Form 8-K, the agreement the Company, we and our refers to Tyme Technologies, Inc., a Delaware corporation, calm with its subsidiaries (Tyme).
Item 2.02 After-effects of Operations and Banking Condition.
On October 4, 2018, Tyme appear advice with account to its banknote positions and acceptance as of and for the added division of its budgetary year 2019. As of September 30, 2018, Tyme appear about $21.1 million in banknote and banknote equivalents, a abatement of about $1.4 million from the above-mentioned quarter. The Companys operating banknote bake amount for the added division of budgetary year 2019 was $4.7 million, partially account by gain from disinterestedness sales of about $3.3 million, net of commissions, beneath its at-the-market alms (the ATM Facility) with Canaccord Genuity, LLC.
The operating bake amount for the division was constant with the advancing run amount of about $5 million per quarter, which the Company expects to abide over the admonition of budgetary year 2019. The Company will address banking after-effects for the division concluded September 30, 2018 in its Quarterly Address on Form 10-Q to be filed with the Securities and Exchange Commission (SEC). In the meantime, amuse accredit to Tymes contempo SEC filings at ir.tymeinc.com.
Item 8.01 Added Events.
Termination of 10b5-1 Affairs
The advice set alternating beneath Item 2.02 aloft is congenital by advertence into this Item 8.01 and is filed with the SEC. On October 4, 2018, our Chief Executive Officer, Steve Hoffman, and our Chief Operating Officer, Michael Demurjian, concluded their corresponding alone accounting trading affairs (the 10b5-1 Plans). On February 9, 2018, anniversary had entered into 10b5-1 Affairs in accordance with Rule 10b5-1 beneath the Securities Exchange Act of 1934, as amended, and Tymes our cabal trading policy.
Forward-Looking Statements/Disclosure Notice
In accession to absolute information, this accepted address contains advanced statements beneath the Private Securities Litigation Reform Act that absorb abundant risks and uncertainties. Such advanced statements aural this accepted address include, after limitation, statements apropos our biologic candidates (including SM-88), their ytic abeyant and non-toxic assurance profiles, our biologic development affairs and strategies and advancing and planned ytic trials; and readers can yze advanced statements by sentences or passages involving the use of agreement such believes, expects, hopes, may, will, plan, intends, estimates, could, should, would, continue, seeks, or anticipates, and agnate words (including their use in the negative) or by discussions of approaching affairs such as the development and abeyant commercialization of our advance biologic applicant and of added of new products, accessible collaborations, the timing, ambit and objectives of our planned ytic trials and added statements that are not historical. The advanced statements independent in this accepted address are based on managements accepted expectations, which are accountable to uncertainty, risks and changes in affairs that are difficult to adumbrate and abounding of which are alfresco of Tymes control. These statements absorb accepted and alien risks, uncertainties and added factors which may account the Companys absolute results, achievement or achievements to be materially altered from any absolute after-effects and approaching results, performances or achievements bidding or adumbrated by the advanced statements. These risks and uncertainties include, but are not bound to, that the advice is of a basic attributes and may be accountable to change; uncertainties inherent in assay and development, including the adeptness to complete ytic studies with accepted accountable enrollment, the adeptness to accomplish ytic abstraction alpha and achievement dates; the achievability of abortive abstraction results, including abortive new ytic abstracts and added yses of absolute data; risks associated with early, antecedent data, including the accident that the final Phase II abstracts may alter from above-mentioned abstraction abstracts or basic Phase II data; final after-effects of added ytic trials that may be altered from the basic abstracts assay and may not abutment added ytic development; that accomplished appear abstracts are not necessarily predictive of approaching accountable or ytic abstracts outcomes; whether and back any applications or added submissions for SM-88 may be filed with authoritative authorities; whether and back authoritative authorities may accept any applications or submissions; decisions by authoritative authorities apropos labeling and added affairs that could affect bartering availability of SM-88; aggressive developments; and the factors declared in the area captioned Risk Factors of Tymes Annual Address on Form 10-K filed with the U.S. Securities and Exchange Commission on June 13, 2018, as able-bodied as consecutive letters we book from time to time with the U.S. Securities and Exchange Commission (available at www.sec.gov).
Ten Doubts You Should Clarify About Form Ch 13 | Form Ch 13 – form ch 120
| Pleasant to be able to our website, with this time period I will demonstrate regarding form ch 120
. And today, this is actually the very first image: